Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jul 14;2015(7):CD010591.
doi: 10.1002/14651858.CD010591.pub2.

Capsaicin for non-allergic rhinitis

Artur Gevorgyan  1 , Christine Segboer, Rob Gorissen, Cornelis M van Drunen, Wytske Fokkens
Affiliations

Capsaicin for non-allergic rhinitis

Artur Gevorgyan et al. Cochrane Database Syst Rev. .

Abstract

Background: There are many forms of rhinitis. Patients are diagnosed with non-allergic rhinitis when anatomic, infectious and allergic aetiologies have been excluded. The symptoms, including nasal congestion, blockage or obstruction, clear rhinorrhoea, sneezing and, less frequently, nasal itching, can range from mild to debilitating. It affects between 25% and 50% of patients with rhinitis. Several medications are widely used in the treatment of non-allergic rhinitis, including oral and topical nasal antihistamines, intranasal and (rarely) systemic corticosteroids, and anticholinergics. Capsaicin, the active component of chili peppers, delivered intranasally, is considered a treatment option for non-allergic rhinitis.

Objectives: To assess the effectiveness of capsaicin in the management of non-allergic rhinitis compared with no therapy, placebo or other topical or systemic medications, or two or more of the above therapies in combination, or different capsaicin regimens.

Search methods: We searched the Cochrane Ear, Nose and Throat Disorders Group Trials Register; the Cochrane Central Register of Controlled Trials (CENTRAL 2015, Issue 5); PubMed; EMBASE; CINAHL; Web of Science; Cambridge Scientific Abstracts; ICTRP and additional sources for published and unpublished trials. The date of the search was 24 June 2015.

Selection criteria: Randomised controlled trials in adult patients with non-allergic rhinitis comparing intranasal capsaicin with no therapy, placebo or other topical or systemic medications, or their combinations.

Data collection and analysis: We used the standard methodological procedures expected by The Cochrane Collaboration.

Main results: We included four studies (five publications) involving 302 participants with idiopathic non-allergic rhinitis. All the included studies described patients with moderately severe, idiopathic non-allergic rhinitis who were between the ages of 16 and 65. Studies had follow-up periods ranging from four to 38 weeks. The overall risk of bias in the studies was either high or unclear (two studies had overall high risk of bias, while two others had low to unclear risk of bias). Using the GRADE system we assessed the evidence as being of low to moderate quality. A meta-analysis was not possible, given lack of similarity of the reported outcomes.Two studies compared capsaicin with placebo. One study reported that capsaicin resulted in an improvement of overall nasal symptoms (a primary outcome) measured on a visual analogue scale (VAS) of 0 to 10. There was a mean difference (MD) of -3.34 (95% confidence interval (CI) -5.24 to -1.44), MD -3.73 (95% CI -5.45 to -2.01) and MD -3.52 (95% CI -5.55 to -1.48) at two, 12 and 36 weeks post-treatment, respectively. Another study reported that, compared to placebo, capsaicin (at 4 µg/puff) was more likely to produce overall symptom resolution (reduction in nasal blockage, sneezing/itching/coughing and nasal secretion measured with a daily record chart) at four weeks post-treatment (a primary outcome). The risk ratio (RR) was 3.17 (95% CI 1.38 to 7.29).One study compared capsaicin to budesonide (an intranasal corticosteroid). This study found that patients treated with capsaicin had a better overall symptom score compared to those treated with budesonide (MD 2.50, 95% CI 1.06 to 3.94, VAS of 0 to 10). However, there were no differences in the individual symptom scores for headache, postnasal drip, rhinorrhoea, nasal blockage, sneezing and sore throat assessed during the last three days of a four-week treatment.One study compared two different regimens of capsaicin administration: five treatments in one day versus five treatments given every two to three days during two weeks. Using daily record charts, the study reported significant improvement of individual symptom scores for rhinorrhoea in patients treated five times per day, however numerical data were not presented. There were no improvements in the other outcomes: rhinorrhoea, nasal obstruction, sneezing and overall nasal symptoms, measured on a VAS.Finally, one of these studies also compared three doses of capsaicin (to placebo). Patients treated with a 1 µg versus 4 µg per puff dose of capsaicin had a worse daily record chart overall symptom score resolution (RR 0.63, 95% CI 0.34 to 1.16).Only one study attempted to measure adverse effects (a primary outcome), however due to methodological issues with the assessment we are unable to draw any conclusions.We sought to include other secondary outcomes (e.g. quality of life measures, treatment dropouts, endoscopic scores, turbinate or mucosal size, cost of therapy), but none of these were measured or reported in the included studies.

Authors' conclusions: Capsaicin may be an option in the treatment of idiopathic non-allergic rhinitis. It is given in the form of brief treatments, usually during the same day. It appears to have beneficial effects on overall nasal symptoms up to 36 weeks after treatment, based on a few, small studies (low-quality evidence). Well-conducted randomised controlled trials are required to further advance our understanding of the effectiveness of capsaicin in non-allergic rhinitis, especially in patients with non-allergic rhinitis of different types and severity, and using different methods of capsaicin application.

PubMed Disclaimer

Conflict of interest statement

Wytske Fokkens received private sector support for research and/or clinical trials related to treatment of allergic and non‐allergic rhinitis from Allergopharma, GlaxoSmithKline (GSK) and Bioinpsire, as well as public sector research support from InterUniversity Attraction Poles (Belgium), ZonMW (The Netherlands), and Global Allergy and Asthma European Network (EU). WJ Fokkens has also received royalties for legal consultation/expert witness testimony for Stallergens. WJF is also the lead author of two of the five included studies, Blom 1997/1998 and van Rijswijk 2003.

Cornelis M van Drunen has received grants form GSK, ALK, Allergopharma, the European Union (GA2LEN, BM4SIT) and the Dutch (NWO) and Flemish Government (FMO) in the field of (non)‐allergic rhinitis and chronic rhinosinusitis.

Artur Gevorgyan was supported by the 2013 Clinical Fellowship of the European Academy of Allergy and Clinical Immunology.

Christine Segboer: no potential conflict of interest.

Rob Gorissen: no potential conflict of interest.

No funds have been received by the authors of the review that relate directly to capsaicin.

Figures

1
1
Process for sifting search results and selecting studies for inclusion.
2
2
'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1 Capsaicin versus placebo, Outcome 1 Overall nasal symptoms 2 weeks post‐treatment.
1.2
1.2. Analysis
Comparison 1 Capsaicin versus placebo, Outcome 2 Overall nasal symptoms 12 weeks post‐treatment.
1.3
1.3. Analysis
Comparison 1 Capsaicin versus placebo, Outcome 3 Overall nasal symptoms 36 weeks post‐treatment.
1.4
1.4. Analysis
Comparison 1 Capsaicin versus placebo, Outcome 4 Daily record chart symptom resolution at 4 weeks post‐treatment (capsaicin 1 μg/puff versus placebo).
1.5
1.5. Analysis
Comparison 1 Capsaicin versus placebo, Outcome 5 Daily record chart symptom resolution at 4 weeks post‐treatment (capsaicin 2 μg/puff versus placebo).
1.6
1.6. Analysis
Comparison 1 Capsaicin versus placebo, Outcome 6 Daily record chart symptom resolution at 4 weeks post‐treatment (capsaicin 4 μg/puff versus placebo).
2.1
2.1. Analysis
Comparison 2 Capsaicin versus budesonide, Outcome 1 Aggregate score during the 4th week of treatment.
2.2
2.2. Analysis
Comparison 2 Capsaicin versus budesonide, Outcome 2 Aggregate relief score during the 4th week of treatment.
2.3
2.3. Analysis
Comparison 2 Capsaicin versus budesonide, Outcome 3 Nasal obstruction (responder/non‐responder analysis) during the 4th week of treatment.
2.4
2.4. Analysis
Comparison 2 Capsaicin versus budesonide, Outcome 4 Headache during the 4th week of treatment.
2.5
2.5. Analysis
Comparison 2 Capsaicin versus budesonide, Outcome 5 Postnasal drip during the 4th week of treatment.
2.6
2.6. Analysis
Comparison 2 Capsaicin versus budesonide, Outcome 6 Rhinorrhoea during the 4th week of treatment.
2.7
2.7. Analysis
Comparison 2 Capsaicin versus budesonide, Outcome 7 Nasal blockage during the 4th week of treatment.
2.8
2.8. Analysis
Comparison 2 Capsaicin versus budesonide, Outcome 8 Sneezing during the 4th week of treatment.
2.9
2.9. Analysis
Comparison 2 Capsaicin versus budesonide, Outcome 9 Sore throat during the 4th week of treatment.
3.1
3.1. Analysis
Comparison 3 Different regimens of capsaicin administration, Outcome 1 UPSIT at 12 weeks post‐treatment.
4.1
4.1. Analysis
Comparison 4 Different doses of capsaicin, Outcome 1 Daily record chart symptom resolution at 4 weeks post‐treatment (capsaicin 1 μg versus 2 μg/puff).
4.2
4.2. Analysis
Comparison 4 Different doses of capsaicin, Outcome 2 Daily record chart symptom resolution at 4 weeks post‐treatment (capsaicin 1 μg versus 4 μg/puff).
4.3
4.3. Analysis
Comparison 4 Different doses of capsaicin, Outcome 3 Daily record chart symptom resolution at 4 weeks post‐treatment (capsaicin 2 μg versus 4 μg/puff).
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD010591

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Blom 1997/1998 {published data only}
    1. Blom HM, Rijswijk JB, Garrelds IM, Mulder PG, Timmermans T, Gerth van Wijk R. Intranasal capsaicin is efficacious in non‐allergic, non‐infectious perennial rhinitis. A placebo‐controlled study. Clinical and Experimental Allergy 1997;27(7):796‐801. - PubMed
    1. Blom HM, Severijnen LA, Rijswijk JB, Mulder PG, Wijk RG, Fokkens WJ. The long‐term effects of capsaicin aqueous spray on the nasal mucosa. Clinical and Experimental Allergy 1998;28(11):1351‐8. - PubMed
Ciabatti 2009 {published data only}
    1. Ciabatti PG, D'Ascanio L. Intranasal capsicum spray in idiopathic rhinitis: a randomized prospective application regimen trial. Acta Oto‐Laryngologica 2009;129(4):367‐71. - PubMed
Havas 2002 {published data only}
    1. Havas TE, Taplin MA. Intranasal neuropeptide depletion using topical capsaicin for the control of symptoms in non‐allergic, non‐infectious perennial rhinitis (NANIPER). Australian Journal of Otolaryngology 2002;5(2):107‐13.
van Rijswijk 2003 {published data only}
    1. Rijswijk JB, Boeke EL, Keizer JM, Mulder PG, Blom HM, Fokkens WJ. Intranasal capsaicin reduces nasal hyperreactivity in idiopathic rhinitis: a double‐blind randomized application regimen study. Allergy 2003;58(8):754‐61. - PubMed

References to studies excluded from this review

Bernstein 2011 {published data only}
    1. Bernstein J. A randomized, double‐blind, parallel trial comparing capsaicin nasal spray with placebo in subjects with a significant component of nonallergic rhinitis. Annals of Allergy, Asthma, and Immunology 2011 Jun 29 [Epub ahead of print]. - PMC - PubMed

References to ongoing studies

NCT02288156 {published data only}
    1. Hellings P. Elaboration of patient‐friendly treatment strategy with capsaicin nasal spray in patients with idiopathic rhinitis. https://clinicaltrials.gov/show/NCT02288156 2014. [NCT02288156]

Additional references

Ameille 2013
    1. Ameille J, Hamelin K, Andujar P, Bensefa‐Colas L, Bonneterre V, Dupas D, et al. Occupational asthma and occupational rhinitis: the united airways disease model revisited. Occupational and Environmental Medicine 2013 Feb 6 [Epub ahead of print]. - PMC - PubMed
Behrendt 2004
    1. Behrendt HJ, Germann T, Gillen C, Hatt H, Jostock R. Characterization of the mouse cold‐menthol receptor TRPM8 and vanilloid receptor type‐1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. British Journal of Pharmacology 2004;141(4):737‐45. - PMC - PubMed
Bousquet 2008
    1. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63 Suppl 86:8‐160. - PubMed
Burns 2012
    1. Burns P, Powe DG, Jones NS. Idiopathic rhinitis. Current Opinion in Otolaryngology & Head and Neck Surgery 2012;20(1):1‐8. - PubMed
Cheng 2006
    1. Cheng J, Yang XN, Liu X, Zhang SP. Capsaicin for allergic rhinitis in adults. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD004460.pub2] - DOI - PMC - PubMed
Cuilty‐Siller 1996
    1. Cuilty‐Siller C, Navaro C, Cruz‐Ponce J, Kuhn F. Comparative clinical and rhinomanometric response to capsaicin and ipratropium bromide in vasomotor rhinitis. Otolaryngology ‐ Head and Neck Surgery. 1996; Vol. 115:P110.
Desrosiers 2011
    1. Desrosiers M, Evans GA, Keith PK, Wright ED, Kaplan A, Bouchard J, et al. Canadian clinical practice guidelines for acute and chronic rhinosinusitis. Journal of Otolaryngology ‐ Head & Neck Surgery 2011;40 Suppl 2:S99‐193. - PubMed
Ellis 2007
    1. Ellis AK, Keith PK. Nonallergic rhinitis with eosinophilia syndrome and related disorders. Clinical Allergy and Immunology 2007;19:87‐100. - PubMed
EPOS 2012
    1. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinology. Supplement 2012;50(23):1‐298. - PubMed
Fokkens 2002
    1. Fokkens WJ. Thoughts on the pathophysiology of nonallergic rhinitis. Current Allergy and Asthma Reports 2002;2(3):203‐9. - PMC - PubMed
Garzaro 2012
    1. Garzaro M, Pezzoli M, Landolfo V, Defilippi S, Giordano C, Pecorari G. Radiofrequency inferior turbinate reduction: long‐term olfactory and functional outcomes. Otolaryngology ‐ Head and Neck Surgery 2012;146(1):146‐50. - PubMed
Gelardi 2008
    1. Gelardi M, Maselli Del Giudice A, Fiorella ML, Soleti P, Gioacchino M, Conti CM, et al. Quality of life in non‐allergic rhinitis depends on the predominant inflammatory cell type. Journal of Biological Regulators and Homeostatic Agents 2008;22(1):73‐81. - PubMed
Georgalas 2012
    1. Georgalas C, Jovancevic L. Gustatory rhinitis. Current Opinion in Otolaryngology & Head and Neck Surgery 2012;20(1):9‐14. - PubMed
Groger 2012
    1. Groger M, Klemens C, Wendt S, Becker S, Canis M, Havel M, et al. Mediators and cytokines in persistent allergic rhinitis and nonallergic rhinitis with eosinophilia syndrome. International Archives of Allergy and Applied Immunology 2012;159(2):171‐8. - PubMed
Handbook 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Higgins 2011
    1. Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Knudsen 2009
    1. Knudsen TB, Thomsen SF, Nolte H, Backer V. A population‐based clinical study of allergic and non‐allergic asthma. Journal of Asthma 2009;46(1):91‐4. - PubMed
Lacroix 1991
    1. Lacroix JS, Buvelot JM, Polla BS, Lundberg JM. Improvement of symptoms of non‐allergic chronic rhinitis by local treatment with capsaicin. Clinical and Experimental Allergy 1991;21(5):595‐600. - PubMed
Marabini 1991
    1. Marabini S, Ciabatti PG, Polli G, Fusco BM, Geppetti P. Beneficial effects of intranasal applications of capsaicin in patients with vasomotor rhinitis. European Archives of Oto‐Rhino‐Laryngology 1991;248(4):191‐4. - PubMed
Meltzer 1999
    1. Meltzer EO, Grant JA. Impact of cetirizine on the burden of allergic rhinitis. Annals of Allergy, Asthma, and Immunology 1999;83(5):455‐63. - PubMed
Molgaard 2007
    1. Molgaard E, Thomsen SF, Lund T, Pedersen L, Nolte H, Backer V. Differences between allergic and nonallergic rhinitis in a large sample of adolescents and adults. Allergy 2007;62(9):1033‐7. - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Robinson 2006
    1. Robinson SR, Wormald PJ. Endoscopic vidian neurectomy. American Journal of Rhinology 2006;20(2):197‐202. - PubMed
Rondon 2012
    1. Rondon C, Campo P, Togias A, Fokkens WJ, Durham SR, Powe DG, et al. Local allergic rhinitis: concept, pathophysiology, and management. Journal of Allergy and Clinical Immunology 2012;129(6):1460‐7. - PubMed
Rondon 2012a
    1. Rondon C, Campo P, Galindo L, Blanca‐Lopez N, Cassinello MS, Rodriguez‐Bada JL, et al. Prevalence and clinical relevance of local allergic rhinitis. Allergy 2012;67(10):1282‐8. - PubMed
Rosenfeld 2007
    1. Rosenfeld RM, Andes D, Bhattacharyya N, Cheung D, Eisenberg S, Ganiats TG, et al. Clinical practice guideline: adult sinusitis. Otolaryngology ‐ Head and Neck Surgery 2007;137(3 Suppl):S1‐31. - PubMed
Sanico 1998
    1. Sanico AM, Philip G, Proud D, Naclerio RM, Togias A. Comparison of nasal mucosal responsiveness to neuronal stimulation in non‐allergic and allergic rhinitis: effects of capsaicin nasal challenge. Clinical and Experimental Allergy 1998;28(1):92‐100. - PubMed
Schroer 2012
    1. Schroer B, Pien LC. Nonallergic rhinitis: common problem, chronic symptoms. Cleveland Clinic Journal of Medicine 2012;79(4):285‐93. - PubMed
Stjarne 1989
    1. Stjarne P, Lundblad L, Anggard A, Hokfelt T, Lundberg JM. Tachykinins and calcitonin gene‐related peptide: co‐existence in sensory nerves of the nasal mucosa and effects on blood flow. Cell and Tissue Research 1989;256(3):439‐46. - PubMed
Van Gerven 2012
    1. Gerven L, Boeckxstaens G, Hellings P. Up‐date on neuro‐immune mechanisms involved in allergic and non‐allergic rhinitis. Rhinology 2012;50(3):227‐35. - PubMed
van Rijswijk 2005
    1. Rijswijk JB, Blom HM, Fokkens WJ. Idiopathic rhinitis, the ongoing quest. Allergy 2005;60(12):1471‐81. - PubMed
Varghese 2010
    1. Varghese M, Glaum MC, Lockey RF. Drug‐induced rhinitis. Clinical and Experimental Allergy 2010;40(3):381‐4. - PubMed

Publication types

LinkOut - more resources